Exclusive: Sudo Biosciences secures $116M to start trials of its oral and topical TYK2 candidates

Su­do Bio­sciences has raised a $116 mil­lion Se­ries B from well-known in­vestors and Sanofi’s VC arm, the transat­lantic biotech told End­points News, as it looks to cap­i­tal­ize on the TYK2 field fol­low­ing the lead of Bris­tol My­ers Squibb and Take­da (by way of Nim­bus Ther­a­peu­tics).

Carmel, IN-based Su­do is at­tempt­ing to carve a niche in the TYK2 space by cre­at­ing a brain-pen­e­trant oral drug that could po­ten­tial­ly treat con­di­tions such as mul­ti­ple scle­ro­sis, which hits close to home for CEO Scott Byrd, whose wife has lived with the dis­ease “for the bet­ter part of her life,” he said in an in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.